Keyphrases
Ablation
5%
Acute Decompensated Heart Failure
30%
Adaptive Servo-ventilation
11%
Adverse Events
6%
All-cause Mortality
10%
Aortic Insufficiency
8%
Arginine Vasopressin
5%
Atrial Fibrillation
21%
B-type Natriuretic Peptide
11%
Beta-blockers
10%
Bosentan
5%
Cardiac Function
6%
Cardiac Output
5%
Cardiac Resynchronization Therapy
8%
Cardiogenic Shock
8%
Cardiovascular Mortality
9%
Catheter
6%
Catheter Ablation
10%
Chronic Heart Failure
5%
Chronic Kidney Disease
8%
Clinical Outcomes
21%
Combination Therapy
6%
Confidence Interval
16%
Congestive Heart Failure
11%
Consecutive Patients
5%
Continuous-flow Left Ventricular Assist Device (CF-LVAD)
11%
Device Implantation
10%
Everolimus
5%
Hazard Ratio
11%
Heart Failure
33%
Heart Failure Hospitalization
8%
Heart Failure Patients
20%
Heart Failure Readmission
5%
Heart Failure with Preserved Ejection Fraction (HFpEF)
10%
Heart Rate
17%
Heart Transplantation
19%
Hyperkalemia
5%
Hyponatremia
5%
Impella
12%
Implantable Left Ventricular Assist Device
5%
Ivabradine
5%
Japan
25%
Japanese Patients
11%
Left Ventricular Assist Device
51%
Left Ventricular Assist Device Implantation
30%
Left Ventricular Assist Device Support
13%
Left Ventricular Assist Device Therapy
5%
Left Ventricular Dysfunction
6%
Left Ventricular Ejection Fraction
12%
Left Ventricular Function
7%
Left Ventricular Remodeling
7%
Lung Fluid
5%
MitraClip
5%
Mitral Regurgitation
5%
Multicenter Registry
5%
Muscle Sympathetic Nerve Activity
7%
Myocytes
5%
Non-valvular Atrial Fibrillation
6%
Odds Ratio
6%
Older Men
6%
Paroxysmal Atrial Fibrillation
6%
Patients with Chronic Heart Failure
10%
Patients with Heart Failure
35%
Poor Prognosis
5%
Prognostic Impact
12%
Pulmonary Arterial Hypertension
8%
Pulmonary Capillary Wedge Pressure
9%
Pulmonary Congestion
5%
Pulmonary Vascular Resistance
5%
Quality of Life
6%
Ramp Test
5%
Remote Dielectric Sensing
12%
Right Heart Catheterization
5%
Right Ventricular Function
6%
Risk Stratification
5%
Severe Aortic Stenosis
10%
Sodium Zirconium Cyclosilicate
5%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
5%
Stage D Heart Failure
7%
Sympathetic Nerve Activity
7%
Systolic Heart Failure
7%
Therapeutic Strategies
9%
Tolvaptan
28%
Transcatheter Aortic Valve Implantation
26%
Transcatheter Aortic Valve Replacement
41%
Transesophageal Echocardiography
5%
Valvular Interventions
7%
Ventilation Therapy
5%
Ventricular Arrhythmia
5%
Ventricular Assist Device
15%
Ventricular Fibrillation
5%
Ventricular Myocytes
6%
Waon Therapy
5%
Medicine and Dentistry
Ablation
11%
Acute Decompensated Heart Failure
5%
Adverse Event
10%
All Cause Mortality
7%
Aortic Insufficiency
10%
Aortic Stenosis
15%
Aortic Valve
5%
Apoplexy
8%
Assisted Circulation
9%
Atrial Fibrillation
24%
Beta Adrenergic Receptor Blocking Agent
6%
Bleeding
5%
Brain Natriuretic Peptide
16%
Cannula
5%
Cardiac Catheterization
6%
Cardiac Resynchronization Therapy
9%
Cardiogenic Shock
8%
Cardiovascular System
11%
Chronic Kidney Disease
7%
Combination Therapy
11%
Congestive Heart Failure
100%
Device Therapy
6%
Dilated Cardiomyopathy
6%
Drug Therapy
5%
Ejection Fraction
8%
Elderly Patient
5%
Hazard Ratio
15%
Heart Failure with Preserved Ejection Fraction
5%
Heart Function
8%
Heart Graft
5%
Heart Left Ventricle Ejection Fraction
14%
Heart Output
5%
Heart Transplantation
21%
Hemodynamic
29%
Ivabradine
5%
Kidney Function
5%
Left Ventricle
5%
Left Ventricular Assist Device
81%
Lung Congestion
6%
Lung Fluid
5%
Mitral Insufficiency
12%
Nerve Conduction
9%
New York Heart Association Class
5%
Odds Ratio
8%
Paroxysmal Atrial Fibrillation
6%
Percutaneous Aortic Valve Replacement
71%
Pulmonary Artery
6%
Pulmonary Artery Occlusion Pressure
8%
Pulmonary Hypertension
8%
Quality of Life
6%
Recurrent Disease
7%
Scoring System
6%
Sympathetic Nerve
8%
Systolic Heart Failure
6%
Thromboembolism
5%
Tolvaptan
12%
Valvular Intervention
8%
Ventricular Assist Device
21%
Ventricular Fibrillation
5%
Ventricular Tachycardia
5%